Abstract

l-Serine is the immediate precursor of d-serine, a major agonist of the N-methyl-d-aspartate (NMDA) receptor. l-Serine is a pivotal amino acid since it serves as a precursor to a large number of essential metabolites besides d-serine. In all non-photosynthetic organisms, including mammals, a major source of l-serine is the phosphorylated pathway of l-serine biosynthesis. The pathway consists of three enzymes, d-3-phosphoglycerate dehydrogenase (PGDH), phosphoserine amino transferase (PSAT), and l-phosphoserine phosphatase (PSP). PGDH catalyzes the first step in the pathway by converting d-3-phosphoglycerate (PGA), an intermediate in glycolysis, to phosphohydroxypyruvate (PHP) concomitant with the reduction of NAD+. In some, but not all organisms, the catalytic activity of PGDH can be regulated by feedback inhibition by l-serine. Three types of PGDH can be distinguished based on their domain structure. Type III PGDHs contain only a nucleotide binding and substrate binding domain. Type II PGDHs contain an additional regulatory domain (ACT domain), and Type I PGDHs contain a fourth domain, termed the ASB domain. There is no consistent pattern of domain content that correlates with organism type, and even when additional domains are present, they are not always functional. PGDH deficiency results in metabolic defects of the nervous system whose systems range from microcephaly at birth, seizures, and psychomotor retardation. Although deficiency of any of the pathway enzymes have similar outcomes, PGDH deficiency is predominant. Dietary or intravenous supplementation with l-serine is effective in controlling seizures but has little effect on psychomotor development. An increase in PGDH levels, due to overexpression, is also associated with a wide array of cancers. In culture, PGDH is required for tumor cell proliferation, but extracellular l-serine is not able to support cell proliferation. This has led to the hypothesis that the pathway is performing some function related to tumor growth other than supplying l-serine. The most well-studied PGDHs are bacterial, primarily from Escherichia coli and Mycobacterium tuberculosis, perhaps because they have been of most interest mechanistically. However, the relatively recent association of PGDH with neuronal defects and human cancers has provoked renewed interest in human PGDH.

Highlights

  • D-Serine is an agonist of the N-methyl-D-aspartate (NMDA) receptor and it is synthesized from L-serine by serine racemase (SR) (Fuchs et al, 2006; Ehmsen et al, 2013; Abe et al, 2014)

  • This work showed that pathway is D-3phosphoglycerate dehydrogenase (PGDH) activity was greater in rat hepatoma cell lines compared to normal liver cells, and correlated the fastest growth rate with the highest PGDH activity

  • Subsequent work (Snell, 1984) showed that this was true in many other tumors as well, and that among the pathway enzymes, tumor growth was most consistently correlated with an increase in PGDH activity

Read more

Summary

INTRODUCTION

D-Serine is an agonist of the N-methyl-D-aspartate (NMDA) receptor and it is synthesized from L-serine by serine racemase (SR) (Fuchs et al, 2006; Ehmsen et al, 2013; Abe et al, 2014). The crystal structure of M. tuberculosis PGDH contains a molecule of tartrate bound at the interface of adjacent ASB domains (Figure 10) E. coli PGDH contains a Gly–Gly sequence (Gly 336–Gly 337 corresponding to positions 397–398 in Figure 3) between the substrate binding domain and the regulatory domain that acts like a hinge and plays a role in the conformational change that takes place upon serine binding and that is responsible for inhibition of activity (Grant, 2011). A previous review (Grant, 2012) summarized the findings of these studies in detail so they will only be briefly summarized here

Coli PGDH
SUMMARY AND PROSPECTIVE
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call